NDA 217660 · Vertex Pharms INC
Trikafta (Copackaged)
Elexacaftor, Ivacaftor, Tezacaftor, Ivacaftor · Oral
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Apr 26, 2023
Approved uses
3
Original approval plus efficacy supplements
Registered trials
29
21 Phase 3, 9 recruiting
FAERS reports
12,580
5,317 serious, 247 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking TRIKAFTA, in both clinical trials and the postmarketing setting [see Adverse Reactions (6) ]. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA . Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating TRIKAFTA. Assess liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test elevations at baseline [see...
What it is approved for
From the label in effect Jun 22, 2026.
TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 6 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ] . If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ( 1 , 12.1 ) If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ( 1 )
Mechanism: Elexacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is increased quantity and function of CFTR at the cell surface, resulting in increased CFTR activity as measured both...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2026 Supplement 8 · Efficacy · priority review OrphanMedication GuideLetterLabel
- Dec 20, 2024 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Apr 26, 2023 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
2 products under this application
- TRIKAFTA (COPACKAGED) · ELEXACAFTOR, IVACAFTOR, TEZACAFTOR 80MG, 60MG, 40MG; IVACAFTOR 59.5MG · GRANULE, ORAL · Prescription
- TRIKAFTA (COPACKAGED) · ELEXACAFTOR, IVACAFTOR, TEZACAFTOR 100MG, 75MG, 50MG; IVACAFTOR 75MG · GRANULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elexacaftor" as an intervention, any sponsor and status, largest first.
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05076149 · 597 participants · Start Oct 27, 2021 · Primary completion May 18, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 170 sites in all
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03525574 · 507 participants · Start Oct 9, 2018 · Primary completion Jan 9, 2023
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Long Beach, California · 110 sites in all
- A Study Evaluating the Long-term Safety of VX-445 Combination TherapyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04043806 · 458 participants · Start Aug 9, 2019 · Primary completion Dec 14, 2022
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; Aurora, Colorado · 97 sites in all
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)Pivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05033080 · 435 participants · Start Sep 14, 2021 · Primary completion May 12, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 139 sites in all
- Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05274269 · 307 participants · Start May 9, 2022 · Primary completion Jul 5, 2023
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Innsbruck, Austria; Brussels, Belgium; Edegem, Belgium · 90 sites in all
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delPivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05331183 · 297 participants · Start Nov 23, 2022 · Primary completion Apr 6, 2027
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Innsbruck, Austria; Brussels, Belgium; Edegem, Belgium · 81 sites in all
- A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)Pivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04058353 · 271 participants · Start Aug 28, 2019 · Primary completion Jun 12, 2020
Drug: ELX/TEZ/IVA; IVA and 1 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Long Beach, California · 93 sites in all
- Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04058366 · 251 participants · Start Dec 5, 2019 · Primary completion Dec 16, 2022
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Tucson, Arizona; Long Beach, California; Palo Alto, California · 84 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infective pulmonary exacerbation of cystic fibrosis823
- headache776
- anxiety635
- cough602
- rash573
- fatigue546
- productive cough545
- weight increased521
- cystic fibrosis513
- abdominal pain upper480
- depression461
- hospitalisation443
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 500 |
| 2020 | 5,170 |
| 2021 | 1,161 |
| 2022 | 1,050 |
| 2023 | 1,297 |
| 2024 | 1,438 |
| 2025 | 1,259 |
| 2026 | 704 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Devínek P, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis.
Lupas D, Chou FY, Hakani MAA, et al. · J Cyst Fibros 2024 · Systematic Review, Meta-Analysis
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, et al. · Lancet 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.
Edwards SJ, Farrar BG, Ennis K, et al. · Health Technol Assess 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Vertex Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.